Skip to main content
. 2022 Mar 18;12:836117. doi: 10.3389/fonc.2022.836117

Table 4.

Associations of SNPs and GRS with OS and PFS of advanced lung adenocarcinoma patients treated with EGFR-TKI stratified by sex.

Sex SNPs/GRS PFS* OS*
HR (95% CI) P value HR (95% CI) P value
Male rs10519613 1.392 (1.034-1.874) 0.029 1.263 (0.897-1.779) 0.181
rs4819554 1.566 (1.123-2.185) 0.008 1.677 (1.113-2.527) 0.013
rs4149570 1.747 (1.267-2.410) 0.001 1.613 (1.112-2.340) 0.012
rs2070600 1.399 (0.938-2.087) 0.099
rs755622 1.699 (1.172-2.463) 0.005
low GRS 1 1
Intermediate GRS 2.016 (1.167-3.482) 0.012 2.984 (1.445-6.159) 0.003
high GRS 3.042 (1.653-5.599) < 0.001 4.466 (2.115-9.430) < 0.001
Female rs10519613 1.152 (0.948-1.401) 0.155 1.312 (1.021-1.687) 0.034
rs4819554 1.238 (1.000-1.533) 0.050 1.177 (0.902-1.535) 0.230
rs4149570 1.172 (0.959-1.433) 0.122 1.123 (0.876-1.439) 0.361
rs2070600 1.289 (0.991-1.676) 0.059
rs755622 1.194 (0.878-1.624) 0.258
low GRS 1 1
Intermediate GRS 1.288 (0.918-1.808) 0.143 0.834 (0.951-1.525) 0.834
high GRS 1.629 (1.105-2.400) 0.014 1.967 (1.176-3.289) 0.010

CI, confidence interval; GRS, genetic risk score; HR, hazard ratio; PFS, progression-free survival; OS, overall survival.

*Adjusted by age, smoking status, ECGO and stages.